Document:

Exhibit 10.6

      

      

      SPONSOR WARRANTS PURCHASE AGREEMENT

      

      

      THIS SPONSOR WARRANTS PURCHASE AGREEMENT, dated as of [●], 2021 (this “Agreement”), is entered into by and between Jackson Acquisition Company, a Delaware corporation (the “Company”), and RJ Healthcare SPAC, LLC, a Delaware limited liability company (the “Purchaser”).

      

      

      WHEREAS, the Company intends to consummate an initial public offering (the “Public Offering”) of the Company’s units (each, a “Unit”)
        consisting of one share of the Company’s Class A common stock, par value $0.0001 per share (a “Share”), and one-half of one redeemable warrant, each whole warrant exercisable for one Share at an exercise
        price of $11.50 per Share, as set forth in the Company’s registration statement on Form S-1, as amended (registration no. 333–254727), related to the Public Offering (the “Registration Statement”) and filed
        under the Securities Act of 1933, as amended (the “Securities Act”);

      

      

      WHEREAS, the Company has entered into an Underwriting Agreement dated as of  [●], 2021 with BofA Securities, Inc., as underwriter (the “Underwriter”), pursuant to which the
        Company has, among other things, granted the Underwriter an option (the “over-allotment option”) to purchase additional Units; and

      

      

      WHEREAS, the Purchaser now wishes to purchase an aggregate of 9,560,000 warrants (or 10,610,000 warrants if the Underwriter’s over-allotment option is exercised in full) (the “Warrants”),
        each Warrant entitling the holder thereof to purchase one Share at an exercise price of $11.50 per Share.

      

      

      NOW THEREFORE, in consideration of the mutual promises contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties to this Agreement
        hereby, intending legally to be bound, agree as follows:

      

      

      AGREEMENT

      

      

      Section 1.          Authorization, Purchase and Sale; Terms of the Warrants.

      

      

      A.          Authorization of the Warrants.  The Company has duly authorized the issuance and sale of the Warrants to the Purchaser.

      

      

      B.          Purchase and Sale of the Warrants.

      

      

      (i)          On the date of the consummation of the Public Offering or on such earlier date as may be mutually agreed upon by the Purchaser and the Company (the “Initial

          Closing Date”), the Company shall issue and sell to the Purchaser, and the Purchaser shall purchase from the Company, 9,560,000 Warrants at a price of $1.00 per Warrant for an aggregate purchase price of $9,560,000 (the “Purchase Price”).  At least one business day prior to the Initial Closing Date, the Purchaser shall pay the Purchase Price, by transfer of immediately available funds in accordance with the Company's instruction,
        to a trust account (the “Trust Account”) designated by the Company at Bank of America, N.A., which Trust Account is maintained by Continental Stock Transfer & Trust Company, as trustee.  On the Initial
        Closing Date, subject to immediately available funds in the amount of the Purchase Price having been deposited into the Trust Account by the Purchaser at least one business day prior to the Initial Closing Date, the Company, at its option, shall
        deliver a certificate evidencing the Warrants purchased on such date duly registered in the Purchaser’s name to the Purchaser, or effect such delivery in book-entry form.

      

      

      
        
          

      

      
      

      

       

      (ii)          On the date of the consummation of each closing, if any, of the over-allotment option in connection with the Public Offering or on such earlier time and date as may be mutually agreed
        by the Purchaser and the Company (each such date, an “Over-allotment Closing Date,” and, each Over-allotment Closing Date (if any) together with the Initial Closing Date, being sometimes referred to herein as
        a “Closing Date,” or the “Closing Dates”), the Company shall issue and sell to the Purchaser, and the Purchaser shall purchase from the Company, 1,050,000 additional
        Warrants (or, if the over-allotment option is not being exercised in full on such Over-overallotment Closing Date, a lesser number of Warrants in proportion to the portion of the over-allotment option that is then being exercised) at a price of
        $1.00 per Warrant for an aggregate purchase price of up to $1,050,000 (if the over-allotment option in connection with the Public Offering is exercised in full).   At least one business day prior to each Over-overallotment Closing Date, the
        Purchaser shall pay the purchase price (with respect to any Over-allotment Closing Date, the “Over-allotment Purchase Price”) for the Warrants being purchased on such Over-allotment Closing Date (such
        Over-allotment Purchase Price being equal to the number of Warrants to be purchased on such date multiplied by $1.00 per Warrant) by wire transfer of immediately available funds to the Trust Account in accordance with the Company’s wiring
        instructions. On the Over-allotment Closing Date, subject to immediately available funds in the amount of the Over-allotment Purchase Price having been deposited into the Trust Account by the Purchaser at least one business day prior to the
        applicable Over-allotment Closing Date, the Company shall, at its option, deliver a certificate evidencing the Warrants purchased on such date duly registered in the Purchaser’s name to the Purchaser, or effect such delivery in book-entry form.

      

      

      C.          Terms of the Warrants.

      

      

      (i)          Each Warrant shall have its terms set forth in a Warrant Agreement to be entered into by the Company and a warrant agent, in connection with the Public Offering (a “Warrant Agreement”).

      

      

      (ii)          On or prior to the time of the closing of the Public Offering, the Company and the Purchaser and, if applicable, the other parties thereto shall enter into a registration rights
        agreement (the “Registration Rights Agreement”) pursuant to which the Company will grant certain registration rights to the Purchaser relating to the Warrants and the Shares underlying the Warrants.

      

      

      Section 2.          Representations and Warranties of the Company.  As a material inducement to the Purchaser to enter into this Agreement and purchase the Warrants, the Company hereby represents and warrants to
        the Purchaser (which representations and warranties shall survive the Closing Dates) that:

      

      

      A.          Organization and Corporate Power.  The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and is qualified to do
        business in every jurisdiction in which the failure to so qualify would reasonably be expected to have a material adverse effect on the financial condition, operating results or assets of the Company.  The Company possesses all requisite corporate
        power and authority necessary to carry out the transactions contemplated by this Agreement and the Warrant Agreement.

      

      

      B.          Authorization; No Breach.

      

      

      (i)          The execution, delivery and performance of this Agreement and the Warrants have been duly authorized by the Company as of the Initial Closing Date.  This Agreement constitutes a valid
        and binding obligation of the Company, enforceable in accordance with its terms, subject to bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other laws of general applicability relating to or affecting creditors’ rights
        and to general equitable principles (whether considered in a proceeding in equity or law).  Upon issuance in accordance with, and payment pursuant to, the terms of the Warrant Agreement and this Agreement, the Warrants will constitute valid and
        binding obligations of the Company, enforceable in accordance with their terms as of the applicable Closing Dates.

      

      

      
        2

        
          

      

      

      

       

      (ii)          The execution and delivery by the Company of this Agreement and the Warrants, the issuance and sale of the Warrants, the issuance of the Shares upon exercise of the Warrants and the
        fulfillment of, and compliance with, the respective terms hereof and thereof by the Company, do not and will not as of the Closing Dates (a) conflict with or result in a breach of the terms, conditions or provisions of, (b) constitute a default
        under, (c) result in the creation of any lien, security interest, charge or encumbrance upon the Company’s capital stock or assets under, (d) result in a violation of, or (e) require any authorization, consent, approval, exemption or other action
        by or notice or declaration to, or filing with, any court or administrative or governmental body or agency pursuant to the certificate of incorporation of the Company or the bylaws of the Company (in effect on the date hereof or as may be amended
        prior to completion of the contemplated Public Offering), or any material law, statute, rule or regulation to which the Company is subject, or any agreement, order, judgment or decree to which the Company is subject, except for any filings required
        after the date hereof under federal or state securities laws.

      

      

      C.          Title to Securities.  Upon issuance in accordance with, and payment pursuant to, the terms hereof and the Warrant Agreement, the Shares issuable upon exercise of the Warrants will
        be duly and validly issued, fully paid and nonassessable.  Upon issuance in accordance with, and payment pursuant to, the terms hereof and the Warrant Agreement, the Purchaser will have good title to the Warrants and the Shares issuable upon
        exercise of such Warrants, free and clear of all liens, claims and encumbrances of any kind, other than (i) transfer restrictions hereunder and under the other agreements contemplated hereby, (ii) transfer restrictions under federal and state
        securities laws, and (iii) liens, claims or encumbrances imposed due to the actions of the Purchaser.

      

      

      D.          Governmental Consents.  Assuming the accuracy of the representations and warranties made by the Purchaser in this Agreement, no permit, consent, approval or authorization of, or
        declaration to or filing with, any governmental authority is required on the part of the Company in connection with the execution, delivery and performance by the Company of this Agreement or the consummation by the Company of any other
        transactions contemplated hereby.

      

      

      E.          Regulation D Qualification.  Neither the Company nor, to its knowledge, any of its affiliates, officers, directors or beneficial stockholders of 20% or more of its outstanding
        securities, has experienced a disqualifying event as enumerated pursuant to Rule 506(d) of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”).

      

      

      Section 3.          Representations and Warranties of the Purchaser.  As a material inducement to the Company to enter into this Agreement and issue and sell the Warrants to the Purchaser, the Purchaser hereby
        represents and warrants to the Company (which representations and warranties shall survive the Closing Dates) that:

      

      

      A.          Organization and Requisite Authority.  The Purchaser possesses all requisite power and authority necessary to carry out the transactions contemplated by this Agreement.

      

      

      B.          Authorization; No Breach.

      

      

      (i)          This Agreement constitutes a valid and binding obligation of the Purchaser, enforceable in accordance with its terms, subject to bankruptcy, insolvency, fraudulent conveyance,
        reorganization, moratorium and other laws of general applicability relating to or affecting creditors’ rights and to general equitable principles (whether considered in a proceeding in equity or law).

      

      

      (ii)          The execution and delivery by the Purchaser of this Agreement and the fulfillment of and compliance with the terms hereof by the Purchaser does not and shall not as of the Closing Dates
        conflict with or result in a breach by the Purchaser of the terms, conditions or provisions of any agreement, instrument, order, judgment or decree to which the Purchaser is subject.

      

      

      
        3

        
          

      

      

      

       

      C.          Investment Representations.

      

      

      (i)          The Purchaser is acquiring the Warrants and, upon exercise of the Warrants, the Shares issuable upon such exercise (collectively, the “Securities”),

        for the Purchaser’s own account, for investment purposes only and not with a view towards, or for resale in connection with, any public sale or distribution thereof.

      

      

      (ii)          The Purchaser is an “accredited investor” as such term is defined in Rule 501(a)(3) of Regulation D under the Securities Act and the Purchaser has not experienced a disqualifying event
        as enumerated pursuant to Rule 506(d) of Regulation D under the Securities Act.

      

      

      (iii)          The Purchaser understands that the Securities are being offered and will be sold to it in reliance on specific exemptions from the registration requirements of the United States
        federal and state securities laws and that the Company is relying upon the truth and accuracy of, and the Purchaser’s compliance with, the representations and warranties of the Purchaser set forth herein in order to determine the availability of
        such exemptions and the eligibility of the Purchaser to acquire such Securities.

      

      

      (iv)          The Purchaser’s decision to enter into this Agreement was not the result of any general solicitation or general advertising within the meaning of Rule 502(c) under the Securities Act.

      

      

      (v)          The Purchaser has been furnished with all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of the Securities which
        have been requested by the Purchaser.  The Purchaser has been afforded the opportunity to ask questions of the executive officers and directors of the Company.  The Purchaser understands that its investment in the Securities involves a high degree
        of risk and it has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect to the acquisition of the Securities.

      

      

      (vi)          The Purchaser understands that no United States federal or state agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the
        Securities or the fairness or suitability of the investment in the Securities by the Purchaser nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

      

      

      (vii)          The Purchaser understands that: (a) the Securities have not been and are not being registered under the Securities Act or any state securities laws, and may not be offered for sale,
        sold, assigned or transferred unless (1) subsequently registered thereunder or (2) sold in reliance on an exemption therefrom; (b) except as specifically set forth in the Registration Rights Agreement, neither the Company nor any other person is
        under any obligation to register the Securities under the Securities Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder; and (c) Rule 144 adopted pursuant to the
          Securities Act will not be available for resale transactions of Securities prior to a Business Combination and may not be available for resales of the Securities for at least one year after a Business Combination, if at all.

      

      

      (viii)          The Purchaser has such knowledge and experience in financial and business matters, knowledge of the high degree of risk associated with investments in the securities of companies in
        the development stage such as the Company, is capable of evaluating the merits and risks of an investment in the Securities and is able to bear the economic risk of an investment in the Securities in the amount contemplated hereunder for an
        indefinite period of time.  The Purchaser can afford a complete loss of its investment in the Securities.

      

      

      
        4

        
          

      

      

      

       

      (ix)          The Purchaser understands that the Private Placement Warrants shall bear a legend  restricting transfers substantially in the form set forth in the Warrant Agreement and be subject to
        appropriate “stop transfer restrictions”.

      

      

      Section 4.          Conditions of the Purchaser’s Obligations.  The obligations of the Purchaser to purchase and pay for the Warrants to be purchased on any Closing Date are subject to the fulfillment, on or
        before such Closing Date, of each of the following conditions:

      

      

      A.          Representations and Warranties.  The representations and warranties of the Company contained in Section 2 shall be true and correct at and as of such Closing Date as though
        then made.

      

      

      B.          Performance.  The Company shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that are required to be performed or
        complied with by it on or before such Closing Date.

      

      

      C.          No Injunction.  No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court
        or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby, which prohibits the consummation of any of the transactions contemplated by this Agreement or the Warrant
        Agreement.

      

      

      D.          Warrant Agreement.  The Company shall have entered into a Warrant Agreement with a warrant agent on terms satisfactory to the Purchaser.

      

      

      E.          Registration Rights Agreement.  The Company shall have entered into a Registration Rights Agreement with the Purchaser and other parties thereto on terms satisfactory to the
        Purchaser.

      

      

      Section 5.          Conditions of the Company’s Obligations.  The obligations of the Company to the Purchaser under this Agreement are subject to the fulfillment, on or before the Closing Dates, of each of the
        following conditions:

      

      

      A.          Representations and Warranties.  The representations and warranties of the Purchaser contained in Section 3 shall be true and correct at and as of the Closing Dates as
        though then made.

      

      

      B.          Performance.  The Purchaser shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that are required to be performed or
        complied with by the Purchaser on or before the Closing Dates.

      

      

      C.          No Injunction.  No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court
        or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby, which prohibits the consummation of any of the transactions contemplated by this Agreement or the Warrant
        Agreement.

      

      

      D.          Warrant Agreement.  The Company shall have entered into a Warrant Agreement with a warrant agent on terms satisfactory to the Company.

      

      

      Section 6.          Termination.  This Agreement may be terminated at any time after March 31, 2021 upon the election by either the Company or the Purchaser upon written notice to the other party if the closing
        of the Public Offering does not occur prior to such date.

      

      

      
        5

        
          

      

      

      

       

      Section 7.          Survival of Representations and Warranties.  All of the representations and warranties contained herein shall survive the Closing Dates.

      

      

      Section 8.          Definitions.  Terms used but not otherwise defined in this Agreement shall have the meaning assigned to such terms in the Registration Statement.

      

      

      Section 9.          Miscellaneous.

      

      

      A.          Successors and Assigns.  Except as otherwise expressly provided herein, all covenants and agreements contained in this Agreement by or on behalf of any of the parties hereto shall
        bind and inure to the benefit of the respective successors of the parties hereto whether so expressed or not.  Notwithstanding the foregoing or anything to the contrary herein, the parties may not assign this Agreement, other than assignments by
        the Purchaser to affiliates thereof.

      

      

      B.          Severability.  Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of
        this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement.

      

      

      C.          Counterparts.  This Agreement may be executed in any number of counterparts, and each of such counterparts shall for all purposes be deemed to be an original, and all such
        counterparts shall together constitute but one and the same instrument. The words “executed”, “execution,” “signed,” “signature,” and words of like import in this Agreement or in any certificate, agreement or document related to this Agreement
        shall include images of manually executed signatures transmitted by facsimile, email or other electronic format (including, without limitation, “pdf,” “tif” or “jpg”) but shall not include (nor shall this Agreement be executed by means of)
        electronic signatures (including, without limitation, DocuSign and AdobeSign). The use of signatures transmitted electronically and electronic records (including, without limitation, any contract or other record created, generated, sent,
        communicated, received, or stored by electronic means) shall be of the same legal effect, validity and enforceability as a manually executed signature or use of a paper-based record-keeping system to the fullest extent permitted by applicable law,
        including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act and any other applicable law, including, without limitation, any state law based on the Uniform Electronic
        Transactions Act or the Uniform Commercial Code.

      

      

      D.          Descriptive Headings; Interpretation.  The descriptive headings of this Agreement are inserted for convenience only and do not constitute a substantive part of this Agreement.  The
        use of the word “including” in this Agreement shall be by way of example rather than by limitation.

      

      

      E.          Governing Law.  This Agreement and the rights and obligations of the parties hereunder shall be construed in accordance with and governed by the laws of New York applicable to
        contracts wholly performed within the borders of such state, without giving effect to the conflict of law principles thereof.  The parties hereto irrevocably submit to the exclusive jurisdiction of any federal court sitting in the Southern District
        of New York or any state court located in New York County, State of New York, over any suit, action or proceeding arising out of or relating to this Agreement.  To the fullest extent they may effectively do so under applicable law, the parties
        hereto irrevocably waive and agree not to assert, by way of motion, as a defense or otherwise, any claim that they are not subject to the jurisdiction of any such court, any objection that they may now or hereafter have to the laying of the venue
        of any such suit, action or proceeding brought in any such court and any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum.

      

      

      F.          Amendments.  This Agreement may not be amended, modified or waived as to any particular provision, except by a written instrument executed by all parties hereto.

      

      

      [Signature page follows]

      

      

      
        6

        
          

      

      

      

       

      IN WITNESS WHEREOF, the parties hereto have executed this Agreement to be effective as of the date first set forth above.

      

      

      	 	
              COMPANY:

            	 
	 	 	 	 
	 	
              JACKSON ACQUISITION COMPANY

            	 
	 	 	 	 
	 	
              By:

            	 	 
	 	 	
              Name: Richard L. Jackson

            	 
	 	 	
              Title:   President and Chief Executive Officer

            	 
	 	 	 	 
	 	
              RJ HEALTHCARE SPAC, LLC

            	 
	 	 	 	 
	 	
              By:

            	 	 
	 	 	
              Name: Richard L. Jackson

            	 
	 	 	
              Title: Managing Member

            	 

      

      

      

      

      

      

      

      

      [Signature Page to Sponsor Warrants Purchase Agreement]Exhibit 10.9

    

    

    Surrender of Shares and

    Amendment No. 1 to the

    Securities Subscription Agreement

    

    

    This Surrender of Shares and Amendment No. 1 to the Securities Subscription Agreement, dated November 22, 2021 (this “Agreement”), is made by and between Jackson Acquisition
      Company, a Delaware corporation (the “Company”), and RJ Healthcare SPAC, LLC, a Delaware limited liability company (the “Subscriber”).

    

    

    WHEREAS, the Company and the Subscriber have entered into that certain Securities Subscription Agreement, dated March 8, 2021 (the “Subscription Agreement”), pursuant to which the
      Subscriber subscribed for an aggregate of 8,625,000 shares of Class B common stock, par value $0.0001 per share of the Company (“Class B Shares”), for an aggregate purchase price of $25,000 and up to 1,125,000
      of such Class B Shares are subject to complete or partial forfeiture by the Subscriber if the underwriter of the Company’s initial public offering (the “IPO”) does not fully exercise its over-allotment option
      as described therein;

    

    

    WHEREAS, in March 2021, the Subscriber transferred 50,000 Class B Shares to David A. Perdue, Jr., 25,000 Class B Shares to each of Marilyn B. Tavenner and Carlos A. Migoya, and 15,000 Class B Shares to Douglas B. Kline;

    

    

    WHEREAS, the Subscriber desires to surrender for no consideration 2,875,000 Class B Shares, resulting in an aggregate of 5,750,000 Class B Shares outstanding and reducing the number of Class B Shares held by the
      Subscriber to 5,635,000 (after taking into account its previous transfer of an aggregate of 115,000 Class B Shares), up to 750,000 of which are subject to complete or partial forfeiture by the Subscriber if the underwriter of the Company’s IPO does
      not fully exercise its over-allotment option as described in the Subscription Agreement;

    

    

    WHEREAS, as a result of such surrender, the per-share purchase price for the Class B Shares will increase from approximately $0.003 per share to approximately $0.004 per share; and

    

    

    WHEREAS, the Company and the Subscriber desire to amend the Subscription Agreement to modify the number of Class B Shares subject to forfeiture in connection with the IPO and the Subscriber desires to provide an
      irrevocable notice of surrender of 2,875,000 Class B Shares to the Company.

    

    

    NOW, THEREFORE, in consideration of the mutual conditions and agreements set forth in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties
      hereto hereby agree as follows:

    

    

    1.          Surrender of Shares.

    

    

    (a)          The Subscriber hereby irrevocably surrenders to the Company for no consideration 2,875,000 Class B Shares and agrees that the Subscriber (together with any successor in
        interest) shall no longer have any rights as a holder of such surrendered Class B Shares, and the Company shall take such action as is appropriate to cancel such surrendered Class B Shares.

    

    

    (b) The Subscriber confirms that the Company has not, as at the date of this letter, issued any share certificates to it.

    

    

    
      1

      
        

    

    2.          Amendment to Subscription Agreement. Section 3.1 of the Subscription Agreement is hereby deleted in its entirety and replaced with a new Section 3.1 to read as follows:

    

    

    “3.1. Partial or No Exercise of the Over-allotment Option. In the event the Over-allotment Option granted to the underwriter of the IPO is not exercised in full, the Subscriber acknowledges and agrees that it
      (or, if applicable, it and any transferees of Shares) shall forfeit any and all rights to such number of Shares (up to an aggregate of 750,000 Shares and pro rata based upon the percentage of the Over-allotment Option exercised) such that immediately
      following such forfeiture, the Subscriber (together with all other holders of Shares) will own an aggregate number of Shares (not including Shares issuable upon exercise of any warrants or any shares of Common Stock purchased by the Subscriber in the
      IPO, in a private placement in connection with the IPO, or in the aftermarket) equal to 20% of the issued and outstanding shares of Common Stock immediately following the IPO. The Subscriber confirms that it has
        previously transferred a total of 115,000 Shares to an officer and certain directors of the Company. The Subscriber and the Company agree that, anything herein to the contrary notwithstanding, any forfeiture of Shares pursuant to the foregoing
        provisions of this Section 3.1 shall not be applicable with respect to any such 115,000 Shares that were previously transferred by Subscriber as aforesaid but that any such forfeiture shall apply solely to Shares owned by the Subscriber (or, if
        applicable, it and any subsequent transferee of Shares).”

    

    

    3.          Agreement Remains Effective. Except as modified herein or amended hereby, the terms and conditions contained in the Subscription Agreement shall continue in full force and effect.

    

    

    4.          Governing Law. This Agreement and the rights and obligations of the parties hereunder shall be construed in accordance with and governed by the laws of New York applicable to contracts wholly performed
      within the borders of such state, without giving effect to the conflict of law principles thereof.

    

    

    5.          Headings and Captions. The headings and captions of the various subdivisions of this Agreement are for convenience of reference only and shall in no way modify or affect the meaning or construction of
      any of the terms or provisions hereof.

    

    

    6.          Counterparts. This Agreement may be executed in one or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts
      have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or any other form of electronic
      delivery, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such signature page were an original thereof.

    

    

    
      2

      
        

    

    IN WITNESS WHEREOF, the undersigned have caused this Agreement to be executed as of the date first written above.

    

    

    	
            JACKSON ACQUISITION COMPANY

          	 
	 	 	 
	
            By:

          	
            /s/ Richard L. Jackson

          	 
	
            Name:

          	
            Richard L. Jackson

          	 
	
            Title:

          	
            Chief Executive Officer, Treasurer and Secretary

          	 
	 	 	 
	 	 	 
	
            RJ HEALTHCARE SPAC, LLC

          	 
	 	 	 
	
            By:

          	
            /s/ Richard L. Jackson

          	 
	
            Name:

          	
            Richard L. Jackson

          	 
	
            Title:

          	
            Managing Member

          	 

    

    

  

  3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}]]